SEC Form 3 FORM 3

UNITED STATES SECURITIES AND EXCHANGE

COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB Number: 0104 Estimated average burden hours per 0.5 response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and A	Address of Repo Kevin T	orting Person [*]	2. Date of Requiring (Month/Da 10/01/20	Statement y/Year)	3. Issuer Name and Ticker or Trading Symbol <u>Inari Medical, Inc.</u> [NARI]						
(Last) (First) (Middle) 6001 OAK CANYON			. 10/01/20		4. Relationship of Reporting Issuer (Check all applicable) Director	10% Owner		File 6. Ir	 5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing 		
(Street) IRVINE	IRVINE CA 92618				Officer (give title below) Chief Financia	Other (specify below) I Officer		(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)									
Table I - Non-Derivative Securities Beneficially Owned											
1. Title of Security (Instr. 4)					2. Amount of Securities Beneficially Owned (Instr. 4)	Form: D (D) or Ir			4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Common Stock					47,355	L	D				
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											
E (1			2. Date Exercisable and Expiration Date Month/Day/Year)		3. Title and Amount of Se Underlying Derivative Se (Instr. 4)		4. Convei or Exei	cise	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
			Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security			5)	
Stock Option		(1)	02/14/2031	Common Stock	11,761	58.44		D			
Stock Option		(2)	02/17/2030	Common Stock	5,293	56		D			

Explanation of Responses:

1. These options were granted on February 15, 2024 under the Inari Medical, Inc. 2020 Incentive Award Plan and are scheduled to become vested and exercisable on a quarterly basis commencing April 1, 2024.

2. These options were granted on February 18, 2023 under the Inari Medical, Inc. 2020 Incentive Award Plan and are scheduled to become vested and exercisable on a quarterly basis commencing April 1, 2023.

<u>/s/ Shannon Trevino,</u> <u>attorney-in-fact for Kevin</u> <u>10/03/2024</u> <u>T Strange</u> ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

With respect to holdings of and transactions in securities issued by Inari Medical Inc. (the Company) the undersigned hereby constitutes and appoints the individuals named on Schedule A attached hereto and as may be amended from time to time, or any of them signing singly, with full power of substitution and resubstitution, to act as the undersigneds true and lawful attorneyinfact to:

1. prepare, execute in the undersigneds name and on the undersigneds behalf, and submit to the United States Securities and Exchange Commission (the SEC) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain and/or regenerate codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC;

2. execute for and on behalf of the undersigned, Forms 3, 4 and 5 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended, and Form 144 in accordance with Rule 144 under the ecurities Act of 1933;

3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, 5, or 144, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and

4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-facts discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigneds responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended, and Rule 144 under the Securities Act of 1933.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, 5 or 144 with respect to the undersigneds holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

[Signature page follows]

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 13 day of September 2024.

Signature: /s/ Kevin T. Strange

Schedule A Individuals Appointed as Attorney-in-Fact with Full Power of Substitution and Resubstitution

Angela Ahmad Shannon Trevino